Navigation Links
GenVec Achieves Second Milestone in Collaboration
Date:12/6/2011

GAITHERSBURG, Md., Dec. 6, 2011 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) today announced that it has achieved the second milestone in its collaboration with Novartis (NYSE: NVS), related to the development of treatments for hearing loss and balance disorders. The milestone was triggered by the successful completion of certain preclinical development activities.

"Completing this milestone reflects sustained progress and we look forward to reaching additional milestones with Novartis in this very exciting program," said Dr. Paul Fischer, GenVec's President and Chief Executive Officer.

About the CollaborationIn January 2010, GenVec entered into a worldwide licensing and collaboration agreement with Novartis to discover and develop novel treatments for hearing loss and balance disorders. Under the terms of the agreement, if certain clinical, regulatory, and sales milestones are met, GenVec is eligible to receive up to $213.6 million, including upfront and milestone payments in addition to royalties on future sales.

In August 2010, we entered into an additional agreement with Novartis, to manufacture clinical trial material for up to two lead product candidates for this program.

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss a
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. GenVec Reports Third Quarter 2009 Financial Results
8. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
10. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
11. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Earlier this month, a report was created by ... Air Force on the performance of vehicles using an ... of fuel made from mustard seeds, offered great potential ... Eco friendly future. In fact, every branch of the ... of foreign oil over the next few years. They ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Supplementing ... offering a promotion for Eppendorf Safe Lock ... to purchase the highest quality tubes at an ... ideal for customers doing chemical, medical, pharmaceutical, and ... who are not regularly able to afford Eppendorf ...
(Date:8/27/2014)... Salt Lake City, Utah (PRWEB) August 27, 2014 ... new construction that will expand its current Salt Lake ... operations currently underway outside of Utah to ultimately create ... the next 20 years. , “Utah is home ... many of whom can be credited with Varian’s success ...
(Date:8/27/2014)... 27, 2014 Rhythm, a biopharmaceutical company developing ... that result in metabolic disorders, announced today that it ... the U.S. Securities and Exchange Commission (SEC) relating to ... common stock. The number of shares to be offered ... yet been determined. Citigroup and Cowen and ...
Breaking Biology Technology:Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2
... VENTURA, Calif., Dec. 12 VivoMetrics Inc., a ... the,appointment of Howard R. Baker to the position ... Paul Kennedy, who will remain with,the company in ... Baker joins VivoMetrics with over 28 years in ...
... Oral Iclaprim, "Rolling" NDA for Intravenous Iclaprim in cSSSI; Electronic ... First Modules ... Arpida Ltd,(SWX: ARPN) announced today the enrolment and dosing of ... iclaprim in the treatment,of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia,(VAP) ...
... for the First Time on 50 mg/Day Dose for PRISTIQ ... Treatment of ... a division of Wyeth (NYSE: WYE ), announces that ... serotonin-norepinephrine reuptake inhibitor (SNRI), showed,that adult patients who received a ...
Cached Biology Technology:VivoMetrics(R) Appoints Howard R. Baker as New President and Chief Executive Officer 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 3First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 4First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6
(Date:8/31/2014)... CAMBRIDGE, MA -- Over the past several decades, malaria diagnosis ... a patient, a technician smears the blood across a glass ... a microscope for the Plasmodium parasite, which causes the disease. ... are in the blood an important measure of disease ... for human error. , A research team from the Singapore-MIT ...
(Date:8/29/2014)... surprising discoveries about the body,s initial responses to ... team found that specialized cells in the intestine ... invasion and are the source of gut inflammation ... , Though aimed at the presence of ... that provides a barrier to protect the body ...
(Date:8/29/2014)... Until recently, little has been known about what ... international team of scientists, one of whom is a ... by showing that genes controlling the development of the ... rabbit domestication., The study was published Aug. 28 in ... questions. It is online at http://www.sciencemag.org/ ., The ...
Breaking Biology News(10 mins):A new way to diagnose malaria 2A new way to diagnose malaria 3The early cost of HIV 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... Rome, Italy: Scientists have discovered that when they ... not only does the procedure make the mice fertile ... their lifespan. The question now is: could ovarian transplants ... Kagawa will tell the 26th annual meeting of the ...
... chemistry sets, ham radio, amateur astronomy, and early computing? ... Today, over 2,000 people from around the world belong ... from microbial fuel cells, low-cost lab equipment, environmental surveillance, ... Synthetic Biology Project at the Woodrow Wilson Center is ...
... WEST LAFAYETTE, Ind. - A Purdue University researcher has found ... their shelf life by about a week. Avtar Handa, ... increases production of a compound that slows aging and delays ... the early online version of The Plant Journal , ...
Cached Biology News:Ovarian transplantation restores fertility to old mice and also lengthens their lives 2Ovarian transplantation restores fertility to old mice and also lengthens their lives 3Gene leads to longer shelf life for tomatoes, possibly other fruits 2
... cyclin required for G1-phase progression and is ... cyclin D2 can phosphorylate pRB when associated ... Human, Mouse, and Rat. Others-not tested. ... suited for neutralization of cyclin D2 activity ...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
... Synthetic peptide corresponding ... Antigen Family: ... Antigen Subfamily: not ... Recommended Storage: Long ...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: